Phase II update – A second patient (92 years old) had a strong reduction in blasts in the bone marrow
No side effects were recorded
Who is entitled to enroll in the trial:
AML /Hi-Risk MDS patients with:
8 weeks of life expectancy.
have no more available treatments.
In cohort 1 (dose=6mg/m^2) three patients were enrolled.
The first patient was alive with this dose for 5 months.
The second patient was alive with this dose for 1.5 months.
The prestigious medical center Georgetown University at Washington DC has sign a contract with ISK to run a clinical trial with patients with mtKRAS pancreas and colon cancers.